DRUG NEWS: Arixtra may be safer for ACS patients

November 2005 
Volume 35  Number 11
Pages 30 - 30
  PDF Version Available!


In a study of 20,000 patients experiencing acute coronary syndrome in 41 countries, the newer anticoagulant fondaparinux (Arixtra) proved just as effective as enoxaparin (Lovenox) at preventing blood clots while cutting the risk of bleeding by half. Bleeding is the most serious adverse reaction associated with anticoagulants.

Purchase Now !

To purchase this item, follow the instructions below. If you’re not already logged in, be sure to enter your login information below to ensure that your item is saved to your File Drawer after you purchase it.

Not a member? Join now for Free!

1) If you're not already logged in, enter your information below to save this item in your File Drawer for future viewing.

User name:


Forgot your user name or password?
2)  If you have a coupon or promotional code, enter it
here.(If not, just click Continue.

Digital Coupon: (optional)

3)  Click Continue to go to the next screen, where
you'll enter your payment details.

Featured Jobs

Benefits of Membership

FREE E-Newsletters
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues

Join our CESaver program to earn up to 100 contact hours for only $34.95
Register Now

Lippincott's NursingCenter.com
Explore a world of online resources

Become a Member